Jun 30, 2025, 13:16

DoD FY25 Peer Reviewed Cancer Research Program Clinical Trial Award

Supports rapid implementation of interventional clinical trials (phase 0–III) addressing at least one FY25 PRCRP topic area and military health focus, to evaluate novel therapeutics, devices, or clinical guidance with the potential for significant impact on cancer treatment and management. Animal studies are not allowed; supportive preclinical data are required.

Eligibility Criteria:

Organizations: Extramural and intramural U.S. or foreign entities—including academic institutions, biotechnology companies, foundations, DOD laboratories, for-profit and non-profit organizations.
Principal Investigator: Independent investigators at or above the rank of Assistant Professor (or equivalent); industry “independent scientists” qualify if analogous. No citizenship restrictions.
Research Scope: Must propose a clinical trial (pilot, first-in-human, phase 0–III) with supportive preclinical data; no new animal studies. Must align to one FY25 PRCRP topic area, one strategic goal, and at least one military health focus area.
Cost Sharing: Not required.

Funding Details:

Total Pool: Approximately $33.6 million to support ~8 awards
Award Cap: Up to $4.2 million total costs (direct + indirect) per award
Period of Performance: Up to 4 years; FY25 funds expire September 30, 2031; awards made by September 30, 2026
Allowable Costs: Clinical trial implementation (subject compensation, trial supplies, coordinator effort), multi-site collaboration travel, one scientific meeting per year; indirect costs per negotiated rates.

Deadlines:

Pre-Application (Preproposal): June 20, 2025, 5:00 p.m. ET
Invitation to Submit Full Application: July 23, 2025
Full Application: September 25, 2025, 11:59 p.m. ET
End of Verification Period: September 30, 2025, 5:00 p.m. ET
Peer Review: November 2025
Programmatic Review: February 2026

Where to Go for Further Information & Application:

Submit both pre-applications and full applications via the eBRAP portal: (select FOA HT942525PRCRPCTA).
Guidelines.

cancer Clinical-Trial-Award eBRAP high-impact research military health OncoDaily Oncology phase I trials Phase II trials phase III trials phase-0-trials PRCRP

ESMO GI 2025 Highlights: OrigAMI-1 Trial on Amivantamab Rechallenge in mCRC

FDA Oncology News: June 2025 Updates

25 Posts Not To Miss From MASCC 2025

Hagop Kantarjian: A legend is Stepping Down

Rahul Banerjee: Excellent News - FDA Eliminates REMS Across CAR-T Products for US Patients